MS. OLGA BARTOV APRN
Prescription History 1417618125
Nurse Practitioner - Family in Palm City, FL

NPI Status: Active since January 05, 2022

Contact Information

4705 SW LORNE CT
PALM CITY, FL
ZIP 34990
Phone: (860) 816-4147

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. OLGA BARTOV APRN, an active Family specialist practicing in Palm City, FL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 51 documented patient claims. Among these therapy options, the most frequently utilized medication is Carbidopa-Levodopa, which accounts for 14 claims alone.

Medication Index

No matching medications currently found on file.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 522
FL State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills112.2
Peer Average Days Supply3,281
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.61

State Avg Cost Per Claim

$47.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Gabapentin

Generic Formulation: GabapentinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.5
Days Supply 465
FL State Average Benchmarks
Peer Average Claims103.0
Peer Average 30-Day Fills177.9
Peer Average Days Supply5,249
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.4% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.77

State Avg Cost Per Claim

$19.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Memantine Hcl

Generic Formulation: Memantine HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.0
Days Supply 520
FL State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills106.3
Peer Average Days Supply3,117
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.3% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $324.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.05

State Avg Cost Per Claim

$47.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Memantine is used to treat moderate to severe confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by blocking the action of a certain natural substance in the brain (glutamate) that is believed to be linked to symptoms of Alzheimer's disease.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 108
FL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply470
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $162.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.53

State Avg Cost Per Claim

$20.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. OLGA BARTOV APRN provides transparency into local medical care patterns within Palm City, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.